News | March 14, 2026
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
This transaction fundamentally strengthens Scinai's CDMO platform
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Subscribe To Our Newsletter & Stay Updated
